$CDXS

De Vre Raymond sold $6K of CDXS

De Vre Raymond sold 2,605 shares of CODEXIS, INC. (CDXS) at $2.37 on 2026-06-11.

Original reporting
SEC EDGAR · De Vre Raymond
Published Jun 12, 2026, 12:19 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 12, 2026, 12:33 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CDXS
Neutral
high confidence
Mentioned
$CDXS
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CDXSNeutralLow
01

Why it matters

The disclosure adds a new, company-specific datapoint (insider selling) but does not include any new business, financial, or regulatory catalyst.

02

Market read

Traders may note insider selling as a minor sentiment input, but there is no fundamental trigger in the text.

03

What to watch

The article provides only the sale details; without context on compensation, tax obligations, or prior trading patterns, the signal-to-noise is low.

Relevance 3/10Novelty 6/10Timing: Filed 2026-06-11 (after-hours) for a 2026-06-11 sale.

Background

SEC Form 4 insider transaction disclosure for CODEXIS, INC. (CDXS).

Company-level read

Ticker impact

$CDXSNeutralHigh confidence
Context

Director De Vre Raymond sold 2,605 shares of CODEXIS (CDXS) in an open-market transaction on 2026-06-11 at $2.37/share.

Expected impact

Low near-term impact; any effect is likely sentiment-noise rather than a fundamental repricing catalyst.

Evidence & confidence

The filing is a disclosed insider sale (not a buy), with no accompanying new operational/regulatory/financial development in the article.

Market effects

No sector-level read-across; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Insider sales can be planned for liquidity/tax and may not reflect bearish fundamentals, especially with no 10b5-1 plan stated.

Key entities

  • CODEXIS, INC.

    Company whose director reported an open-market sale of shares via SEC Form 4.

  • De Vre Raymond

    Director who sold 2,605 shares on 2026-06-11.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CDXSMedAI 8/10

Codexis (CDXS) Q2 2026 Earnings Call Transcript

Codexis (CDXS) reported Q2 2026 revenue of $14.9M, down from $15.3M in Q2 2025. Product revenue rose to $13.2M, while R&D revenue fell to $1.7M. Net loss narrowed to $12.0M. The company guided full-year revenue to $72M-$76M and maintained a high 60% gross margin target. It plans to invest $25M in a GMP facility and expects a 30-fold increase in siRNA market demand by 2035. CDXS has 14 commercial products and 15 clinical programs in Phase II/III. Management highlighted progress in ECOsynthesis pl

$CDXSMed

CODEXIS, INC. (CDXS): Results of Operations and Financial Condition

CODEXIS, INC. (CDXS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Codexis Reports Second Quarter 2026 Financial Results Reports revenue of $14.9 million for the second quarter of 2026, company reiterates full-year financial guidance Shared new advances in RNA therapeutic manufacturing at TIDES US showing that its ECO Synthesis ® Ma

$CDXSMed

CODEXIS, INC. (CDXS): Results of Operations and Financial Condition

CODEXIS, INC. (CDXS) filed an SEC Form 8-K — Results of Operations and Financial Condition. 8-K false 0001200375 0001200375 2026-07-23 2026-07-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23,